Diagen signs new distribution agreement with SpeeDx
Oct 24 2017 Read 596 Times
Sydney, Australia-based SpeeDx has announced a distribution agreement with Scandinavian clinical laboratory supplier Diagen to supply its polymerae chain reaction product lines to hospitals and research facilities across Sweden, Norway and Denmark.
The PlexPCR® range will allow Diagen’s customers to obtain complex diagnostic information on sexually transmitted infections or other infectious diseases from a single, cost-effective test. The agreement will also give them access to the ResistancePlus MG assay. This is the first CE-IVD test to simultaneously detect Mycoplasma genitalium and genetic markers for azithromycin resistance, as recommended by the new European guidelines on M. genitalium resistance screening in the management of non-gonococcal urethritis.
“Scandinavia is home to some important thought leaders influencing sexual health and STI testing practices across Europe,” said Colin Denver, CEO of SpeeDx. “We see our partnership with Diagen as key to offering the best service to laboratories across these important markets.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Determination of heroin in street drug samples with printable surface enhanced Raman scattering (P-SERS) - Advances in Protein Sample Preparation: Centrifugation i...
View all digital editions
Dec 14 2018 Kathmandu, Nepal
Jan 16 2019 Tokyo, Japan
Jan 28 2019 Dubai International Convention & Exhibition Centre
Jan 30 2019 Tokyo, Japan
Jan 31 2019 Paris, France